Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2025-04-29 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-04-29 English
Director Appointment 2 pages 196.2KB
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Lyn Cobley to the Board of Directors of Mesoblast. It details her background, the company's business, and includes forward-looking statements. There is no financial data, no report attached or referenced as being published, and no mention of voting results or regulatory filings. The content focuses on a change in the company's board composition, which fits the category of Board/Management Information (MANG). The document length (7809 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2025-04-28 English
Initial Director's Interest Notice 2 pages 246.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares held directly and indirectly, and notes the date of appointment of the director. There is no financial performance data, no report or presentation content, and the document is a formal notification of a director's shareholding interests upon appointment. This matches the definition of Director's Dealing filings, which report personal share transactions or holdings by company directors. The document length is short and focused solely on director interests, confirming it is not a broader report or announcement. Therefore, the correct classification is Director's Dealing (DIRS).
2025-04-28 English
6-K
Regulatory Filings
2025-04-24 English
Appendix 3Y for Gregory George 3 pages 283.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and details changes in securities holdings by a company director, including dates, number of securities held, and nature of transactions. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure related to insider trading or director shareholdings. There is no financial performance data, earnings information, or report publication content. The content matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives.
2025-04-23 English
6-K
Regulatory Filings
2025-04-17 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.